Systemic Therapy Update on <sup>177</sup>Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update - ASCO | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
ASCO
2023
Systemic Therapy Update on <sup>177</sup>Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update
Document
Analyser ce document
